

The background of the slide is a light blue and white pattern. It features several stylized, dark blue Y-shaped antibody molecules scattered across the page. There are also faint, hatched circular shapes and three vertical rectangular strips, each containing three horizontal lines, representing test results. A large, dark blue rectangular box is positioned in the lower right quadrant, containing the main title and subtitle in white text. A small yellow rectangular box with the text 'ENG' is located to the left of the main text box.

Immunoblot

Technology for the determination of specific antibodies

ENG

Reliable and robust immunoblot kits


Immunoblot kits enable the simultaneous detection of multiple markers in serum, plasma, cerebrospinal, and synovial fluid. They are an important tool for the differential diagnosis of diseases with similar symptoms. They are used for the confirmation of borderline or positive ELISA.

Processing can be done automatically or manually. More precise evaluation can be achieved with easy-to-use software which can be downloaded for free on our website.

An innovative antigen composition and in-house production ensure the tests are of the upmost quality with a high sensitivity and specificity.

BLOT-LINE Test principle


A method using **highly specific recombinant antigens** that are transferred on nitrocellulose membrane.



(Western) BLOT Test principle

A method using electrophoretically separated **whole-cell antigens** that are transferred to a nitrocellulose membrane.

BLOT-LINE kit



Clinical application

- Confirmatory method for screening of serological methods (CLIA, ELISA, etc.)
- Differential diagnosis
- **Infectious serology:** Anaplasma phagocytophilum, Bordetella sp., Borrelia sp., CMV, Chlamydia sp., EBV, Helicobacter pylori, Mycoplasma pneumoniae, Toxocara sp., Toxoplasma gondii, Treponema pallidum, Yersinia sp.
- **Autoimmunity:** ANA, ANCA-3













User comfort

- Ready-to-use components
- Colour-coded strips
- Positive and Negative controls
- Control line on the strip
- Interchangeable components
- Easy assay procedure
- Possibility of software evaluation

Advantages

- Easy interpretation and reproducibility of results
- High diagnostic sensitivity and specificity of tests
- Compatibility with all commercial immunoblot processing systems
- Customer support
- Identical assay procedure for all of the tests

Summary protocol

| Step | Test steps |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
|  | 1. Pipette Universal solution 2.5 ml |
|  | Strips soaking 10 min. at room temperature - Shaker |
|  | 3. Aspirate |
|  | Dilute samples - serum/plasma 1:51 (30 µl + 1.5 ml) - cerebrospinal fluid 1:2 (0.75 ml + 0.75 ml) - synovial fluid 1:17.5 (90 µl + 1.5 ml) |
|  | 5. Pipette Controls and diluted samples 1.5 ml |
|  | 6. Incubate 30 min. at room temperature - Shaker |
|  | 7. Aspirate samples and wash strips with 1.5 ml of Universal solution 3-times for 5 min. - Shaker |
|  | 8. Pipette Conjugate 1.5 ml |
|  | 9. Incubate 30 min. at room temperature - Shaker |
|  | 10. Aspirate Conjugate and wash strips with 1.5 ml of Universal solution 3-times for 5 min. - Shaker |
|  | 11. Pipette Substrate solution (BCIP/NBT) 1.5 ml |
|  | 12. Incubate 15 min. at room temperature - Shaker |
|  | 13. Aspirate Substrate solution and wash strips with 2 ml of distilled water 2-times for 5 min. - Shaker |
|  | 14. Dry and evaluate strips |

Workflow

1. Strip processing – 2 hours
2. Strip drying and sticking
3. Protocol scanning
4. Evaluation and data output

For software evaluation
use office scanner



Evaluation

Software evaluation of the Immunoblot results

Software evaluation is an easy and fast way to get standardized results of laboratory tests. Result processing is user-friendly and straightforward, and the software solution significantly reduces workload and increases efficiency.




Automation

Possibility of automated processing using any open Immunoblot instrument

The complex solution of Immunoblot TestLine kits and RoboBlot

- Fully automated processing of the kits
- Minimization of manual handling and operating time
- Control of the entire process using Immunoblot software and touch screen analyzer
- Connectivity to LIS
- Full compatibility of RoboBlot™, BLOT-LINE kits and Immunoblot Software (TestLine)



Safety

- Pipetting with disposable plastic tips
- Level detection using a pressure sensor
- Bar code reader for samples

Control and evaluation

- Touch screen device control, LAN communication with LIS
- Integrated camera for scanning strips at the end of the run (200-300 dpi)
- Connection with the evaluation program Immunoblot Software (TestLine)

Capacity

- High throughput – 50 samples
- Flexibility – 5 different methods simultaneously

Certification

CE marked; 98/79EC (IVDD); EN 61326-1:2006; EN 61326-2-6:2006; EMC Directive 2004/108/EEC

IMMUNOBLOT kits for the diagnostics of Anaplasmosis


Introduction

Human granulocytic anaplasmosis (HGA) is a disease caused by *Anaplasma phagocytophila* bacteria. Clinically, the disease can manifest itself in various ways – from entirely asymptomatic to rather serious forms. Characteristic manifestations may include: fever, headache, muscle and joint aches, skin alterations (erythema migrans similar to Lyme borreliosis, mostly accompanied by maculopapular rash and hemorrhage), hepatosplenomegaly and lymphadenopathy. Antibodies are detectable approximately two weeks after the outbreak of the infection, which is why acute infections (30-60% positivity) are not always diagnosed correctly. During the convalescence time we usually find positivity in 70-90% of samples.

Test characteristics

| <u>Immunoblot</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|----------------------------|-------------------------------|-------------------------------|
| BLOT-LINE Anaplasma IgG | 92.0% | 94.0% |
| BLOT-LINE Anaplasma IgM | 91.4% | 99.0% |

Antigens



p44 – main antigen of antibody response to HGA

Asp62 – surface protein; works as a membrane transporter

OmpA – surface protein of outer membrane; lipoprotein associated with peptidoglycans; significant marker of virulence

* In case of positive results within the *Anaplasma* screening it is recommended to perform further examination to confirm the HGA

IMMUNOBLOT kits for the diagnostics of *pertussis* and *parapertussis*

Introduction

B. pertussis and *B. parapertussis* are very closely related species, producing similar virulence factors.

Bordetella pertussis is considered to be the main cause of whooping cough. Before the introduction of vaccination, the disease had been one of the most serious diseases of infants and children.

B. pertussis causes severe forms of the disease, while *B. parapertussis* causes milder forms. This is due to the fact that the bacteria *Bordetella parapertussis* do not produce a pertussis toxin. The milder infection of *B. parapertussis* can be the main cause of prolonged bronchitis.

Postvaccination and postinfection immunity acquired after the disease caused by *B. pertussis* do not protect from the disease caused by *B. parapertussis*!


Clinical application

- Method for differentiation of postinfection and postvaccination antibodies (due to IgA antibodies presence)
- Method for proof of acute infection
- Method for differential diagnostics of *B. pertussis* and *B. parapertussis*

Test characteristics

| Pathogens | Diagnostic Sensitivity | Diagnostic Specificity |
|-------------------------------------|------------------------|------------------------|
| <i>Bordetella pertussis</i> IgA | 95.5% | 99.9% |
| <i>Bordetella pertussis</i> IgG | 99.9% | 99.9% |
| <i>Bordetella parapertussis</i> IgA | 99.9% | 99.9% |
| <i>Bordetella parapertussis</i> IgG | 88.9% | 99.9% |

Antigens



B. pertussis

PT – Pertussis toxin (45 kDa) – basic virulence factor, specific only for *B. pertussis*; the most important pertussis antigen

FHA – *B. pertussis* filamentous hemagglutinin – adhesive protein, important immunogen; selected part of the sequence with high specificity

ACT – Adenylate cyclase toxin (CyaA)

– important virulence factor of *B. pertussis*; antiphagocytic factor during infection

TCF – Tracheal colonization factor

– protein produced only by *B. pertussis* strain, not by *B. parapertussis*; protein adhesin, that binds to ciliated epithelial cells of respiratory tract

B. parapertussis

Pertactin – Outer membrane protein (75 kDa) of virulent *B. parapertussis* strains

FimN – Fimbriae N – protein adhesin; it is not produced by *B. pertussis*

EntA – Entericidin A – membrane lipoprotein

BLOT-LINE
Bordetella

IMMUNOBLOT kits for the diagnostics of Lyme Borreliosis

Introduction

Lyme borreliosis is a multisystem disease caused by the bacterial spirochete *Borrelia burgdorferi*.

The specific clinical sign of **early localised stage** is erythema migrans (EM), the characteristic lesion spreading from the site of a tick bite. **Early disseminated stage** may include nonspecific symptoms as for example lymphadenopathy, later arthritis, carditis and early neuroborreliosis, EM multiple, borreliac lymphocytoma and inflammatory changes of other organs.

Untreated borreliosis develops to the **late stage**. Specific presentation seen at this stage can be acrodermatitis chronica atrophicans that involves various organ manifestations. The symptoms can persist for years. In later stages of the disease antibiotic treatment becomes sometimes ineffective.

Human granulocytic anaplasmosis (HGA) is a disease caused by *Anaplasma phagocytophila* bacteria.


Clinically, the disease can manifest itself in various ways – from entirely asymptomatic to rather serious forms. Characteristic pain may include: fever, headache, muscle and joint aches, skin alterations (erythema migrans similar to Lyme borreliosis, mostly accompanied by maculopapular rash and hemorrhage), hepatosplenomegaly and lymphadenopathy.

Antibodies are detectable approximately two weeks after the outbreak of the infection, which is why acute infections (30–60% positivity) are not always diagnosed correctly. During the convalescence time we usually find positivity in 70–90% of samples.

Clinical application

- Immunodominant antigens from individual *Borrelia* species – *B. afzelii*, *B. garinii*, *B. burgdorferi* sensu stricto
- Recombinant antigen p44 from *Anaplasma phagocytophila* – useful for differential diagnosis of HGA
- Recombinant antigen TpN17 for exclusion of cross-reactivity with *Treponema pallidum*
- Possible to detect *Borrelia* antibodies in cerebrospinal fluid

Antigens



Test characteristics

| <u>Immunoblot</u> | Borrelia | | Anaplasma | |
|----------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
| BLOT-LINE Borrelia/HGA IgG | 99.3% | 99.4% | 92.3 | 96.9% |
| BLOT-LINE Borrelia/HGA IgM | 99.2% | 99.3% | 94.7% | 97.1% |

Antigens summary

Diagnostic importance of **BLOT-LINE Borrelia/HGA IgG**

| | |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VlsE Ba VlsE Bg VlsE Bs | Variable major protein-like sequence, expressed Species specific antigen Main antigen of early and late antibody response to LB Significantly increases test sensitivity (approx. 90% of samples of positive sera and CSF react in this antigen band) |
| p83 | Main extracellular protein (product of p100 degradation) Late antibody response antigen Highly immunoreactive antigen, typical of neuroborreliosis |
| p 58 Bg OppA-2 (Oligopeptide permease 2) | Membrane transporter, is considered a marker of disseminated stage of Lyme disease |
| p41 | Inner part of flagellin Highly specific antigen of early antibody response |
| p39 | BmpA (glycosaminopeptide receptor) Antigen of late antibody response Significant antigen for advanced disseminated form of LB, often associated with Lyme arthritis |
| OspB | Outer surface protein B Antigen of late antibody response |
| OspA Ba OspA Bg OspA Bs | Outer surface protein A Antigen of late antibody response, typical of neuroborreliosis |
| OspC | Outer surface protein C Antigen of early antibody response |
| p17 | DbpA (Decorin-Binding protein A) Antigen of early and late antibody response, typical of neuroborreliosis |
| NapA Bs | Neutrophil activating protein A - strong immunogen, main marker of Lyme arthritis pathogenesis |
| p44 | Main antigen of antibody response to HGA |
| TpN17 | Highly specific membrane protein of <i>Treponema pallidum</i> |

Diagnostic importance of **BLOT-LINE Borrelia/HGA IgM**

| | |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VlsE Bg | Expressed part of variable major protein-like sequence, significant for IgG antibody response, species-specific antigen |
| p83 | Main extracellular protein (product of p100 degradation) |
| p41 | Inner part of flagellin Highly specific antigen of early antibody response |
| p39 | BmpA (glycosaminopeptide receptor) Antigen of late antibody response Significant antigen for advanced disseminated form of LB, often associated with Lyme arthritis |
| OspC Ba OspC Bg OspC Bs OspC Bsp | Outer surface protein C – main antigen of early antibody response, immunodominant marker of IgM antibody response; species-specific antigen (Ba – <i>B. afzelii</i> , Bg – <i>B. garinii</i> , Bs – <i>B. burgdorferi sensu stricto</i> , Bsp – <i>B. spielmanii</i>) |
| p44 | Main antigen of antibody response to HGA |


Monospecific IMMUNOBLOT kits

for the diagnostics of Lyme Borreliosis

Advantages

- Immunodominant antigens from individual *Borrelia* species
- Possible to detect *Borrelia* antibodies in cerebrospinal fluid

Antigens



BLOT-LINE *Borrelia afzelii* IgG

BLOT-LINE *Borrelia garinii* IgG

- recombinant antigens: VlsE, p83, p41, p39 (BmpA), OspA, OspC, p17 (DbpA)

BLOT-LINE *Borrelia b. sensu stricto* IgG

- recombinant antigens: VlsE, p83, p41, p39 (BmpA), OspB, OspA, OspC, p18 (OspE)

BLOT-LINE *Borrelia afzelii* IgM

BLOT-LINE *Borrelia garinii* IgM

- recombinant antigens: VlsE, p83, p41, p39 (BmpA), OspC

Test characteristics

| <u>Pathogens</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|------------------------------------------------|-------------------------------|-------------------------------|
| BLOT-LINE <i>Borrelia afzelii</i> IgG | 97.3% | 99.9% |
| BLOT-LINE <i>Borrelia afzelii</i> IgM | 96.6% | 98.0% |
| BLOT-LINE <i>Borrelia garinii</i> IgG | 97.1% | 99.9% |
| BLOT-LINE <i>Borrelia garinii</i> IgM | 97.6% | 99.9% |
| BLOT-LINE <i>Borrelia b. sensu stricto</i> IgG | 96.3% | 99.9% |
| BLOT-LINE <i>Borrelia b. sensu stricto</i> IgM | 97.4% | 99.9% |

IMMUNOBLOT kit for the diagnostics of CMV infection

Introduction


Human cytomegalovirus (CMV, Human Herpesvirus 5, HHV 5) is a member of the Herpesviridae family. Primary infection of CMV occurs mainly in childhood or adolescence. The infection can be transmitted in different ways (e.g. respiratory apparatus, digestive or urogenital tract). Clinically, the disease process is usually asymptomatic or mild (fever, fatigue, mononucleosis symptoms). Dormant infections where the virus survives can be reactivated – generally by changes in host-virus relations (pregnancy, serious disease, stress, immunosuppressive treatment). Reinfection is possible with a different strain of CMV. During the acute stage of infection, convalescence and reactivation of the disease, the virus is exuded in saliva and urine. CMV infection during pregnancy causes developmental defects (virus is easily transmitted through the placenta and affects the fetus). During primary infection mother-to-infant

transmission of the virus (i.e. via placenta) occurs in 1/3 to 1/2 of cases; however, during the reactivation stage, transplacental transmission occurs in only 1% of cases.

Test characteristics

| <u>Pathogens</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|------------------|-------------------------------|-------------------------------|
| CMV IgG | 95.9% | 99.0% |
| CMV IgM | 96.5% | 99.0% |

Antigens



p150 Tegument protein UL32

A strong immunogen of the late stage of infection (late antigen), it does not develop in the early stage. Detectable in the IgG class in higher titres even in reactivation.

p65 Tegument protein UL83

In the IgM class – one of the markers of the early stage of infection
In the IgG class – rather typical for the late stage or infection reactivation

p52 CM2 protein; UL44

In the IgM class – an important marker of the early stage of primary infection
In the IgG class – reactivity rather in the late stage, or infection reactivation

p28 Tegument protein UL99

A strong immunogen; it may develop in late stages of infection.

BLOT-LINE
CMV

IMMUNOBLOT kits for the diagnostics of *Chlamydia* sp.

Introduction

In terms of human health, the most important *Chlamydia* pathogens are *Chlamydia trachomatis* and *Chlamydia pneumoniae*. *Chlamydia psittaci* is primarily an animal pathogen, which can be transmitted to humans.

Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen, causing venereal diseases in humans worldwide. The most vulnerable group is young people between 15 and 30 years of age. Urogenital chlamydia infections often occur in the form of “post-gonococcal inflammation”. Cervical chlamydia infection is currently considered to be one of the risk factors for uterine cervix carcinoma. Chlamydia trachomatis is also the most frequent cause of sterility in both men and women.


Chlamydia pneumoniae is the most widely spread Chlamydiaceae species in the human population. In recent years, the number of acute and chronic infections has increased. Primary infection generally occurs between 5 and 18 years of age. Major clinical symptoms include: rhinitis, sinusitis, otitis media, pharyngitis, bronchitis, atypical pneumonia with non-productive cough and indistinctive auscultatory findings.

Chlamydia psittaci can cause human diseases with atypical pneumonia-like (avian strains) or placentitis-like (mammal strains) manifestation.

Test characteristics

| <u>Pathogens</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|---------------------------|-------------------------------|-------------------------------|
| Chlamydia pneumoniae IgA | 98.8% | 99.9% |
| Chlamydia pneumoniae IgG | 97.7% | 98.2% |
| Chlamydia pneumoniae IgM | 95.0% | 99.0% |
| Chlamydia trachomatis IgA | 97.4% | 98.2% |
| Chlamydia trachomatis IgG | 98.2% | 98.0% |
| Chlamydia psittaci IgA | 99.9% | 99.9% |
| Chlamydia psittaci IgG | 99.9% | 99.9% |

Antigens



Chlamydia pneumoniae

MOMP Cp – dominant major outer membrane protein (species specific) – structural protein; metabolic function

MOMP1 – isoform, produced by posttranslational modification

OMP2 Cp – outer membrane protein (species specific) – structural protein of Chlamydia outer membrane complex

OMP4 – outer membrane protein

OMP5 – outer membrane protein

P54 – immunodominant outer antigen, highly specific to *Ch. pneumoniae* – sensitive marker for diagnosis of acute infection

Chlamydia trachomatis

MOMP Ct – dominant major outer membrane protein (species specific) – structural protein; metabolic function

OMP2 Ct – outer membrane protein (species specific) – structural protein of Chlamydia outer membrane complex


HSP60 – heat shock protein (GroEL); marker of chronic infection

Chlamydia psittaci


MOMP Cps – dominant major outer membrane protein (species specific) – structural protein; metabolic function

OMP2 Cps – outer membrane protein (species specific) – structural protein of Chlamydia outer membrane complex

Reactivity of different diagnostic kits in a group of positive samples



Reactivity of different diagnostic kits in a group of negative samples



IMMUNOBLOT kits for the diagnostics of Epstein-Barr virus infection


Introduction

Epstein-Barr virus (EBV) belongs to a group of herpesviruses (HHV4). The source of the infection is an infected person. The virus is transmitted via droplet infection or direct contact. EB virus is an aetiological agent of infectious mononucleosis (IM) and is also related to Burkitt's lymphoma and nasopharyngeal carcinoma. 90% of the infections will occur in childhood. IM develops after an incubation period (1-2 months). EBV does not disappear completely from the body after the primary infection, it remains in latent state in the body and can be reactivated.

Test Characteristics

| <u>Pathogens</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|-------------------|-------------------------------|-------------------------------|
| BLOT-LINE EBV IgA | 95.4% | 98.2% |
| BLOT-LINE EBV IgG | 99.9% | 98.6% |
| BLOT-LINE EBV IgM | 92.7% | 99.0% |

Antigens



Recombinant antigens:

EBNA-1 – Epstein-Barr nuclear antigen 1; in the IgG class, an important diagnostic marker of late phase or reactivation of the infection; in IgM class detectable antibodies for 2-4 months after primary EBV infection, may also appear also in reactivation

VCA-p18 – Viral Capsid Antigen p18; an important marker of late phase of infection; IgG antibodies do not appear in primary infections; IgM antibodies can be detected in early phase of the infection

VCA-p23 – Viral Capsid Antigen p23; antibodies to this antigen can be detected at all stages of infection in IgG and IgM class, IgG antibodies persist in the body for a long time

EA-D – Early Antigen Diffuse p54; BMRF1; an additional marker of acute EBV infection, antibodies detectable in IgG and IgM class, even in the latent phase of primary infection

**BLOT-LINE
EBV**

IMMUNOBLOT kits for the diagnostics of *Helicobacter* infection

Introduction

Helicobacter pylori belongs in the genus *Helicobacter*. Morphologically, it is a Gram-negative, microaerophilic bacterium. It is found as a pathogen in patients with infection of the gastric mucosa, particularly in the area of pyloric antrum and duodenum. It is a causative agent of B-type chronic gastritis, which is linked to the development of gastric ulcers. In this case, *H. pylori* is detected in 100% of individuals. *H. pylori* infection is often associated with dyspepsia. Active chronic gastritis can further develop in the atrophy of stomach lining and increase the risk of gastric carcinoma.

The factors of *H. pylori* pathogenicity are based on both the morphologic structure of the bacteria cells (helix-shaped curved rod, flagella) and its ability to produce extracellular enzymes and cytotoxins (e.g. urease, catalase, protease, VacA and CagA).


Bacterial strains can be pathogenic or facultatively pathogenic. Their virulence depends on the qualitative

and quantitative representation of the above mentioned factors. Their pathogenesis is also influenced by a host response. Resistant strains are isolated mainly from unsuccessfully treated patients.

Test characteristics

| <u>Pathogens</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|---------------------------------------------|-------------------------------|-------------------------------|
| BLOT-LINE <i>Helicobacter pylori</i> IgA | 95.2% | 99.9% |
| BLOT-LINE <i>Helicobacter pylori</i> IgG | 96.9% | 99.9% |

Antigens



BLOT-LINE
Helicobacter pylori

IMMUNOBLOT kits for the diagnostics of *Mycoplasma* infection

Introduction

Mycoplasma pneumoniae is a primary pathogenic agent of the human respiratory tract. It causes pneumonia accompanied by fever, nausea, ague, cough and fatigue. The disease is prolonged but well curable with antibiotics. The pathogen is airborne, spread especially in dense gatherings of children, particularly during spring and autumn months.

Primary infection is indicated by **IgM** antibody increase (1-2 weeks after the infection). The antibody level reaches its maximum after 1 month from the beginning of the infection and antibodies may persist for more than 1 year.

IgA antibodies are usually produced later than IgM and their level often decreases earlier. IgA antibodies determination is relevant when IgM antibodies are absent or in case of reinfection.


IgG antibodies may rise already 2-3 weeks after appearance of symptoms. The maximum is reached after a longer period (even 6 months). Antibodies persist more than one year. Some cases of antibody persistence longer than 4 years were reported. In case of reinfection, it is necessary to evaluate dynamics of antibodies in paired samples collected after 1 - 2 weeks.

It is crucial to examine all three classes of antibodies and sometimes even perform reinvestigation of paired samples for proper evaluation of serological findings.

Test characteristics

| Pathogens | Diagnostic Sensitivity | Diagnostic Specificity |
|-----------------------------|-------------------------------|-------------------------------|
| BLOT-LINE Mycoplasma IgA | 93.3% | 99.5% |
| BLOT-LINE Mycoplasma IgG | 96.2% | 99.0% |
| BLOT-LINE Mycoplasma IgM | 96.7% | 99.2% |

Antigens



- P1** – Adhesin; the most important protein, a major virulence factor
- p30** – Cytadhesin p30; the second most important protein, a major virulence factor
- p116** – Adhesin, a major virulence factor
- p65** – Surface protein; proline-rich P65 protein
- HMW3** – Cytadherence high molecular weight 3; adhesion-promoting protein
- Mgp3** – Adhesion-promoting protein

BLOT-LINE
Mycoplasma

IMMUNOBLOT kit for the diagnostics of Toxocariasis

Introduction

Larval toxocariasis is a human parasitic disease caused by the larval stage of a dog roundworm – *Toxocara canis* and cat roundworm – *Toxocara cati*.

The infection is characterized by the presence of migrating larvae (larva migrans) in various organs. The *Toxocara* larvae hatching from infectious eggs in the human intestine penetrate the intestinal wall and migrate hematogenously into the liver, lungs, CNS, eyes, musculature and other organ systems. Larvae migration generates several clinical pathologies in the patient, such as visceral larva migrans, ocular toxocariasis and neurotoxocariasis.

Diagnosis of a disease is based on the evaluation of a data set: anamnesis, clinical manifestation and laboratory tests results.


Clinical application

- Differentiation of specific and non-specific fractions of the ES antigen by immunoblot
- Confirmation of ELISA test results as well as confirmation of ambiguous results obtained due to cross-reactions with other helminthoses.

Test characteristics

| <u>Pathogens</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|-------------------|-------------------------------|-------------------------------|
| BLOT Toxocara IgG | 90.9% | 99.0% |

Antigens



Excretory-secretory ('ES') antigen isolated from cultured larvae of *Toxocara canis*

TES 120 – set of secreted mucins Tc-muc1 | Tc-muc4 | surface coat antigens | sensitive and specific for detection of toxocariasis

TES 70 – non-specific lectin | associated with the nematode body cuticle

TES 40, 55 – non-specific glycoproteins

TES 32 – the most frequent associated with nematode body cuticle | specificity for binding of saccharides (mannose and/or galactose) | sensitive and specific for detection of toxocariasis

TES 26 – phosphatidylenolamine binding protein | sensitive and specific for detection of toxocariasis

BLOT-LINE
Toxocara

IMMUNOBLOT kit for the diagnostics of Toxoplasmosis

Introduction

Toxoplasmosis is a widespread parasitic disease caused by protozoan *Toxoplasma gondii*. Primary hosts are members of the feline family. Humans and most warm-blooded animals can be infected by either primarily infected food (insufficiently heat-treated meat) or by ingestion of oocysts (secondary contaminated food or contaminated fingers, objects, etc.).

Acquired toxoplasmosis in immunocompetent individuals is usually asymptomatic or can manifest itself with flu-like symptoms and has no lasting ill effects.

Severe life-threatening infections (encephalitis, hepatitis, chorioretinitis, myocarditis, generalized form of the disease) may develop in immunocompromised patients usually because of a reactivation of a latent infection.

Congenital toxoplasmosis is caused by transmission of infection from mother to foetus and it might result in severe damages of the foetus (brain calcification, hydrocephalus, vision disorders, mental affections), still birth or abortion.


Clinical application

- Useful method to trace immune profile of mothers' and new-borns' sera – determination of congenital toxoplasmosis

Test characteristics

| <u>Immunoblot</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|-----------------------------|-------------------------------|-------------------------------|
| BLOT-LINE Toxoplasma IgA | 95.2% | 99.1% |
| BLOT-LINE Toxoplasma IgG | 95.6% | 98.0% |
| BLOT-LINE Toxoplasma IgM | 95.6% | 98.0% |

Antigens



SAG1 p30; a highly immunogenic and antigenic surface antigen involved in the activation of strong immune response of tachyzoites during the acute phase of toxoplasmosis. A good serological marker for antibodies against *T. gondii* in the acute and chronic phases of infection; high titres of IgG, IgM and IgA.

MIC3 p90; is strong adhesin and one of the major vaccine candidates. It is a dimeric 90 kDa micronemal cysteine-rich protein. It is expressed in tachyzoite, bradyzoite and sporozoite and has excellent immune properties.

GRA1 p24; a highly immunogenic protein whose reactivity correlates with the chronic phase of the disease to a large extent.

GRA7 p29; expressed in all infectious forms of toxoplasma. It elicits a strong antibody response in the acute phase of infection. It is considered an important diagnostic tool, suitable for the chronic phase of infection.

GRA8 p35; highly immunogenic protein, more suitable for the diagnosis of acute toxoplasmosis than chronic infections

SAG2 p22; a major surface protein known as a binding ligand, characterised by good antigenicity and immunogenicity. Effective for the detection of IgG antibodies in patients with acute toxoplasmosis.

**BLOT-LINE
Toxoplasma**

IMMUNOBLOT kits for the diagnostics of Syphilis

Introduction

Syphilis (lues) is a sexually transmitted disease caused by spirochaeta *Treponema pallidum subsp. pallidum*. The disease is spread predominantly by sexual intercourse with an infected individual, however in approximately 5-10% of cases the infection is transmitted in another way (from mother to child, rarely by contact with infected blood or by dermal manifestations).

In case that an expectant mother suffers from an untreated primary or secondary acquired form of syphilis, the disease can be passed to the unborn infant which results in abortion or infection of the foetus and its severe damages (congenital syphilis).

In some cases the asymptomatic congenital form of syphilis can appear with manifestation between 7 and 19 year of life.


Clinical application

- Confirmation of treponemal and non-treponemal tests
- Determination of IgG and IgM antibodies enables to distinguish between new and previous infection

Test characteristics

| <u>Pathogens</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|----------------------------|-------------------------------|-------------------------------|
| BLOT-LINE Treponema IgG | 98.0% | 99.9% |
| BLOT-LINE Treponema IgM | 97.6% | 99.9% |

Antigens



Highly specific antigens:

TpN47
TpN17
TpN15

Specific antigen:

TpN41

BLOT-LINE
Treponema pallidum

IMMUNOBLOT kits for the diagnostics of *Yersinia* infections

Introduction

Yersinia are pathogenic gram-negative bacteria of the Enterobacteriaceae family and their representatives *Y. enterocolitica* and *Y. pseudotuberculosis* are known as human enteropathogens. The carriers are latently infected warm-blooded animals.

The infection occurs orally after the ingestion of contaminated water or food.

The clinical signs of *Y. enterocolitica* and *Y. pseudotuberculosis* infection are very similar. Differences are mostly observed in intestinal complaints, pseudoappendicitis and sepsis. The most widespread *Y. enterocolitica* causes diarrhoea in humans, accompanied by diarrhoea of the small intestine, colon or appendix. It can also cause joint inflammation and enlargement of the lymph nodes. Complications such as acute reactive arthritis, erythema nodosum, acute glomerulonephritis and myocarditis may develop during the infection.

Skin symptoms appear about 1–6 weeks after the infection. In some cases, *Y. enterocolitica* may also persist for years in the intestinal mucosa and in the lymphatic tissues.

Antibody response


IgA, IgG and IgM antibodies can be detected in the initial phase after contact with virulent *Yersinia* factors. IgA and IgM titres will decrease after several months.

IgG class antibodies persist longer and can be detected for longer than one year. IgG antibodies may persist in some cases throughout the life.

Test characteristics

| <u>Pathogen</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|-----------------|-------------------------------|-------------------------------|
| Yersinia IgA | 94.2% | 99.9% |
| Yersinia IgG | 97.8% | 99.9% |
| Yersinia IgM | 90.0% | 99.9% |

Antigens



- YopB** – YopB *Yersinia* outer protein, transmembrane protein
- YopD** – *Yersinia* outer protein, transmembrane protein
- YopE** – *Yersinia* outer protein
- YopH** – *Yersinia* outer protein
- YopM** – *Yersinia* outer protein
- YopN** – *Yersinia* outer protein
- LcrV** – Low calcium response Virulence, important for YopD a YopB secretion
- Ail** – Attachment-invasion locus protein early phase, involved in the adhesion and invasion process, and allows *Yersinia* to survive outside the host cell, a significant virulence factor
- Invasin** – surface adhesin that binds to $\beta 1$ integrins on the surface of target cells and is important particularly in the first stage of infection, a virulence factor
- YstB** – heat-stable enterotoxin B, responsible for the virulence and pathogenicity of *Y. Enterocolitica* strains, biotype 1A
- YscM-Y.ent** – Yop proteins translocation protein M (specific for *Y. enterocolitica*)
- YscM-Y.pst** – Yop proteins translocation protein M (specific for *Y. pseudotuberculosis*)

BLOT-LINE
Yersinia

IMMUNOBLOT kits for the diagnosis of antibodies against neutrophil cytoplasm and GBM

Introduction

Antineutrophil cytoplasmic antibodies (ANCA) are a group of antibodies directed against cytoplasm antigens of neutrophilic granulocytes and monocytes. ANCA examinations are considered basic tests in immunological laboratories. The determination of ANCA is of great importance, in particular in case of suspected acute vasculitis of small vessels, with severe pulmonary impairment or renal failure, but also in some non-vasculitic clinical syndromes such as inflammatory bowel diseases, e.g. ulcerative colitis. The most common target antigens of ANCA-associated vasculitis are proteinase 3 or myeloperoxidase.


Antibodies against **proteinase 3 (PR3)** are referred to as c-ANCA fluorescent subtype, namely cytoplasmic antibodies (granular cytoplasmic fluorescence). PR3 is a neutral serine proteinase 3, also known as Wegener's autoantigen. Antibodies against PR3 are a highly specific marker in diagnosing Wegener's granulomatosis.

Antibodies against **myeloperoxidase (MPO)** are referred to as p-ANCA subtype, since they form a perinuclear fluorescence pattern. This ANCA fluorescent subtype includes other antibodies such as antibodies against lactoferrin, cathepsin G, or elastase. However, in at least 60% of p-ANCA reactivity cases, the main antigen is MPO. Anti-MPO antibodies are primarily considered an important indicator for progressing nephritis; they are largely present in patients with severe renal impairment. They are also important for diagnosing Churg-Strauss syndrome and microscopic polyangiitis. The presence or absence of antibodies against MPO and PR3 in combination with the positivity of antinuclear antibodies may be regarded as a differentiating marker between ANCA-associated vasculitis and SLE-induced vasculitis.

Anti-GBM antibodies (glomerular basal membrane; Goodpasture's antigen) are important for the diagnosis of glomerulonephritis, which may be accompanied by pulmonary haemorrhage (Goodpasture's pulmo-renal syndrome). Due to clinical symptoms similar with systemic vasculitis, it is appropriate to concurrently carry out the tests for anti-GBM and ANCA antibodies. In all cases, the activity and severity of the disease closely correlates with the concentration

of antibodies. Thus, the information about the determined levels of antibodies can also be used in monitoring disease progression.

Antigens



**BLOT-LINE
ANCA**

Myeloperoxidase (MPO)

– a highly specific sign for the diagnosis of rapidly progressive nephritis, necrotising glomerulonephritis; a positive response in 70-90% of patients with severe renal impairment.

Churg-Strauss Syndrome (CSS), microscopic polyangiitis (MPA) and other vasculitis.

Proteinase 3 (PR3)

– a highly specific serological sign for the diagnosis of Wegener's granulomatosis. Microscopic polyarteritis, Churg-Strauss syndrome, mild systemic sclerosis, ulcerative colitis.

Basal membrane of glomeruli (Goodpasture's antigen, GBM)

– diagnostically significant antibodies in glomerulonephritis; Pulmo-renal Goodpasture's syndrome (rapidly progressive glomerulonephritis, in 2/3 of patients with pulmonary haemorrhage).

Test characteristics

| <u>Pathogen</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|-----------------|-------------------------------|-------------------------------|
| MPO | 91.1% | 91.9% |
| PR3 | 93.5% | 96.7% |
| GBM | 100.0% | 95.5% |

IMMUNOBLOT kits for the diagnosis of Systemic autoimmune diseases


Introduction

Determination of antinuclear antibodies is important for diagnosis of systemic auto-immune diseases. These organ non-specific autoantibodies are directed to intracellular antigens located mainly in the nucleus of the cell. Their detection can indicate the presence of some systemic autoimmunopathologic process – especially: systemic lupus erythematoses (SLE), Sjögren's syndrome (SS), scleroderma, mixed connective tissue disease (MCTD), systemic sclerosis, polymyositis and dermatomyositis.

An important group of antinuclear antibodies represent antibodies against ENA (extractable nuclear antigens: SS-A/Ro, SS-B/La, Sm, RNP, Scl-70 and Jo-1). They are mainly ribonucleoproteins and nuclear enzymes.

The group of antinuclear antibodies also includes antibodies against nucleic acids (ssDNA, dsDNA), complexes of nuclear proteins (DNP, RNP) and histones.

Antigens




Test characteristics

| <u>Immunoblot</u> | <u>Diagnostic Sensitivity</u> | <u>Diagnostic Specificity</u> |
|-------------------|-------------------------------|-------------------------------|
| BLOT-LINE ANA | 96.6% | 97.4% |

BLOT-LINE ANA

Clinical Data

Detection of individual antigens for group of patients with SLE – results of BLOT-LINE ANA (n=65)



Ordering information

BLOT-LINE

Infectious serology

| Cat. No. | Product | No. of Tests |
|----------|-----------------------------------------|--------------|
| ApGL10 | BLOT-LINE Anaplasma IgG | 10 |
| ApML10 | BLOT-LINE Anaplasma IgM | 10 |
| BpAL20 | BLOT-LINE Bordetella IgA | 20 |
| BpGL20 | BLOT-LINE Bordetella IgG | 20 |
| BpML20 | BLOT-LINE Bordetella IgM | 20 |
| BGL020 | BLOT-LINE Borrelia/HGA IgG | 20 |
| BML020 | BLOT-LINE Borrelia/HGA IgM | 20 |
| BaGL20 | BLOT-LINE Borrelia afzelii IgG | 20 |
| BaML20 | BLOT-LINE Borrelia afzelii IgM | 20 |
| BgGL20 | BLOT-LINE Borrelia garinii IgG | 20 |
| BgML20 | BLOT-LINE Borrelia garinii IgM | 20 |
| BsGL20 | BLOT-LINE Borrelia b. sensu stricto IgG | 20 |
| BsML20 | BLOT-LINE Borrelia b. sensu stricto IgM | 20 |
| CAL020 | BLOT-LINE Chlamydia IgA | 20 |
| CGL020 | BLOT-LINE Chlamydia IgG | 20 |
| CpAL20 | BLOT-LINE Chlamydia pneumoniae IgA | 20 |
| CpAG20 | BLOT-LINE Chlamydia pneumoniae IgG | 20 |
| CpAM20 | BLOT-LINE Chlamydia pneumoniae IgM | 20 |
| CtAL20 | BLOT-LINE Chlamydia trachomatis IgA | 20 |
| CtGL20 | BLOT-LINE Chlamydia trachomatis IgG | 20 |
| CMGL20 | BLOT-LINE CMV IgG | 20 |
| CMML20 | BLOT-LINE CMV IgM | 20 |
| EBAL20 | BLOT-LINE EBV IgA | 20 |
| EBGL20 | BLOT-LINE EBV IgG | 20 |
| EBML20 | BLOT-LINE EBV IgM | 20 |
| HpAL20 | BLOT-LINE Helicobacter IgA | 20 |
| HpGL20 | BLOT-LINE Helicobacter IgG | 20 |
| MyAL20 | BLOT-LINE Mycoplasma IgA | 20 |
| MyGL20 | BLOT-LINE Mycoplasma IgG | 20 |
| MyML20 | BLOT-LINE Mycoplasma IgM | 20 |
| TpGL20 | BLOT-LINE Treponema IgG | 20 |
| TgAL20 | BLOT-LINE Toxoplasma IgA | 20 |



FOLLOW US

BIOVENDOR.GROUP

DIAGNOSTIC METHODS – IMMUNOBLOT

| | | |
|--------|--------------------------|----|
| TgGL20 | BLOT-LINE Toxoplasma IgG | 20 |
| TgML20 | BLOT-LINE Toxoplasma IgM | 20 |
| TpML20 | BLOT-LINE Treponema IgM | 20 |
| YAL020 | BLOT-LINE Yersinia IgA | 20 |
| YGL020 | BLOT-LINE Yersinia IgG | 20 |
| YML020 | BLOT-LINE Yersinia IgM | 20 |

Autoimmunity

| Cat. No. | Product | No. of Tests |
|----------|------------------|--------------|
| ANC3L20 | BLOT-LINE ANCA-3 | 20 |
| ANAL20 | BLOT-LINE ANA | 20 |

WESTERN BLOT

| Cat. No. | Product | No. of Tests |
|----------|-------------------|--------------|
| TcGB16 | BLOT Toxocara IgG | 16 |

RELATED PRODUCTS

| Cat. No. | Product |
|----------|---------------------|
| SwIm03 | Immunoblot Software |

**TestLine Clinical Diagnostics Ltd.**

Krizikova 68, 612 00 Brno, Czech Republic
+420 549 121 203
sales@testlinecd.com
www.testlinecd.com



Company is certified to the quality management system standards ISO 9001 and ISO 13485 for in vitro diagnostics.